Advertisement
Canada markets open in 1 hour 33 minutes

  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CAD/USD

    0.7292
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    81.70
    +0.13 (+0.16%)
     

  • Bitcoin CAD

    90,719.45
    +1,408.58 (+1.58%)
     

  • CMC Crypto 200

    1,376.63
    -6.03 (-0.44%)
     

  • GOLD FUTURES

    2,354.30
    +7.40 (+0.32%)
     

  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     

  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     

  • NASDAQ futures

    20,031.25
    +112.00 (+0.56%)
     

  • VOLATILITY

    12.59
    +0.11 (+0.88%)
     

  • FTSE

    8,236.76
    +31.65 (+0.39%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • CAD/EUR

    0.6796
    +0.0009 (+0.13%)
     

SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024

SI-BONE, Inc.
·1 min read
SI-BONE, Inc.
SI-BONE, Inc.

SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston. Management will be hosting a fireside chat on Tuesday, June 18, at 3:40 p.m. Eastern Time / 12:40 p.m. Pacific Time.

Investors interested in listening to the conference call may do so by registering at this link: https://wsw.com/webcast/truist5/sibn/2067200. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,700 surgeons in performing a total of more than 100,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 130 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.

ADVERTISEMENT

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

iFuse Bedrock Granite, iFuse-TORQ, SI-BONE and iFuse INTRA are registered trademarks of SI-BONE, Inc. ©2024 SI-BONE, Inc. All Rights Reserved.

Investor Contact: Saqib Iqbal investors@si-bone.com